

You are cordially invited to a royalty free

DOLUTEGRAVIR

COMPULSORY LICENSE

PARTY

When: NOW!

Where: Algeria, Azerbaijan, Belarus, Brazil,
Bulgaria, China, Colombia, Kazakhstan,
Mexico, Romania, Russia, and Turkey

RSVP to **#DolutegravirParty**



Lifesaving dolutegravir is recommended by WHO for first- and second-line HIV treatment in all populations including children 20kg + above. People taking dolutegravir face less mental health related side effects & are less likely to become resistant to it than those using efavirenz. But so far it ain't no party for upper middle income countries excluded from pricing deals and voluntary licences granted by pharma company ViiV.

Despite demands from HIV activists for a realistic access strategy AND attempts by governments to negotiate affordable prices, ViiV has been playing hide and seek with dolutegravir through a selective licensing strategy and filing multiple abusive patents extending market monopoly.

At USD 8,718, the price of dolutegravir is 140 times more in countries excluded from the license than those included at USD 60. In Mexico, the price is USD 2,629, 1738% more than efavirenz at USD 143. Already, over 80% of the Mexican government's spending on ARVs goes to patented medicines.

We cannot wait any longer while ViiV plays its malicious games with our lives. It is time for governments to join the party and revoke all secondary patents on dolutegravir AND issue COMPULSORY LICENSES to ensure access to affordable generics of optimal dolutegravir based treatment NOW!